[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100494310":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":21,"centralContacts":25,"locations":32,"responsibleParty":46,"collaborators":30,"id":49,"slug":50,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":51,"sex":57,"minAge":58,"maxAge":30,"enrollmentInfo":59,"targetDuration":30,"studyType":62,"phases":63,"briefSummary":65,"conditions":66,"keywords":68,"overallStatus":34,"whyStopped":30,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},{"fullName":5,"class":6},"Dartmouth-Hitchcock Medical Center","OTHER",[8],{"label":9,"type":6,"description":10,"interventionNames":11},"Treatment Arm","Treatment Phase: Patients will be treated with 17b-estradiol until disease progression. At this point, the patient will end protocol therapy",[12],"Drug: Estradiol",[14],{"type":15,"name":16,"description":17,"armGroupLabels":18,"otherNames":19},"DRUG","Estradiol","Estradiol is a therapeutic option for the treatment of advanced ER+ breast cancer",[9],[20],"Estrace",[22],{"name":23,"affiliation":5,"role":24},"Muhammad Azfal, MD","PRINCIPAL_INVESTIGATOR",[26],{"name":27,"role":28,"phone":29,"phoneExt":30,"email":31},"Research Nurse","CONTACT","1-800-639-6918",null,"Cancer.Research.Nurse@dartmouth.edu",[33],{"facility":5,"status":34,"city":35,"state":36,"zip":37,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":30},"RECRUITING","Lebanon","New Hampshire","03756","United States","US",{"type":41,"coordinates":42},"Point",[43,44],-72.25176,43.64229,{"lat":44,"lon":43},{"type":24,"investigatorFullName":47,"investigatorTitle":48,"investigatorAffiliation":5,"oldNameTitle":30,"oldOrganization":30},"Muhammad.Z.Afzal","Associate Professor of Medicine","100494310","phase-2-study0200174022sch740-estradiol-for-er-advanced-breast-cancer-esther-100494310",false,"NCT05716516","STUDY02001740;22SCH740: Estradiol For ER+ Advanced Breast Cancer (ESTHER)","Phase II Study of Estradiol Therapy to Target ER-Mutant and ER-Wild-Type ER+ Metastatic or Advanced Breast Cancer","ESTHER","Inclusion Criteria:\n\n* Post-menopausal women with ER+ breast cancer.\n* Metastatic or locoregional recurrence not amenable to treatment with curative\n* intent.\n* Received ≥1 prior line of endocrine-based therapy (e.g., including tamoxifen, aromatase inhibitors, fulvestrant, or combinations) in the advanced\u002Fmetastatic setting\n\nExclusion Criteria:\n\n* During the study Treatment Phase with 17b-estradiol, no concurrent anti-cancer therapies are allowed with the following exceptions:\n\n  * Exception: Trastuzumab is allowed for the treatment of subjects with a history of HER2+ disease, and will be used at the physician's discretion.\n  * Exception: Anti-resorptive bone therapies (e.g., bisphosphonates, denosumab) are permitted.\n* Any investigational cancer therapy in the last 3 weeks.\n* Known CNS disease, unless clinically stable for ≥ 3 months.\n* History of any of the following:\n\n  * Deep venous thrombosis.\n  * Pulmonary embolism.\n  * Stroke.\n  * Acute myocardial infarction.\n  * Congestive heart failure.\n  * Previous malignancy not treated with curative intent, or with an estimated recurrence risk ≥30%.","FEMALE","18 Years",{"count":60,"type":61},36,"ESTIMATED","INTERVENTIONAL",[64],"PHASE2","Determine whether subjects harboring ESR1-mutant\u002Famplified breast cancer have a higher rate of clinical benefit from 17b-estradiol therapy than subjects with ESR1-wild-type breast cancer",[67],"Metastatic Breast Cancer",[69,70,71,72],"Metastatic","Locally advanced","Estradiol therapy","Estrogen therapy","2026-04-30",{"date":75,"type":76},"2026-05-05","ACTUAL",{"date":78,"type":76},"2023-05-04",{"date":80,"type":61},"2027-05",{"name":5,"class":6},1]